[The agenda of the first day of the 2026 national talks ended at 6 p.m. Chairman of Tonghua Jinma and Dongguang Pharmaceutical personally participated in the battle] On September 5, reporters learned from the on-site negotiation of the 2026 National Medical Insurance Catalog and the price negotiation of the commercially insured innovative drug catalog that the agenda of the first day of the national talks ended at around 6 p.m. The reporter noticed that in the afternoon session, representatives from a number of GLP-1 hypoglycemic drugs that had passed the preliminary review were gathered together, which may mean that the track is ushering in intensive negotiations, including Innovent Biologics’ Masidutide, Pfizer’s Enoglutide Injection, etc. Chairman Zhang Yufu personally participated in the negotiations for Tonghua Jinma's new Alzheimer's drug Avicridine Succinate Tablets. He left with a smile after completing the negotiations. Zhang Yingjun, chairman of Dongyangguang Pharmaceutical, also led a team to participate in the on-site negotiations. The last company representative to leave the afternoon session was from Simcere Pharmaceuticals. The company's new insomnia drug Dalilaysan Hydrochloride Tablets are on the preliminary review list for national negotiation and commercial insurance for innovative drugs. In addition, the acute ischemic stroke drug Edaravone Dexbobornol Sublingual Tablets and others have passed the preliminary review. In addition, the reporter noticed that the overall expression of corporate representatives in the afternoon session was relatively serious after appearing. (Reporters Lu Afeng and Yu Miao)